Get the Stockscreener App
30.80
4.72%
-1.51
Assembly Biosciences Inc stock is traded at $30.80, with a volume of 70,259.
It is down -4.72% in the last 24 hours and down -12.07% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$32.31
Open:
$32.24
24h Volume:
70,259
Relative Volume:
0.52
Market Cap:
$486.85M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-2.2782
EPS:
-13.5194
Net Cash Flow:
$22.49M
1W Performance:
-4.19%
1M Performance:
-12.07%
6M Performance:
+69.71%
1Y Performance:
+77.44%
1-Day Range:
$30.60
$32.95
1-Week Range:
$30.60
$34.69
52-Week Range:
$7.75
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
30.78 | 511.05M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.16 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.22 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.06 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.27 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.79 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
(ASMB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Stock Price Up 4% – Time to Buy? - Defense World
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Trading 4% HigherHere's What Happened - MarketBeat
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB - Defense World
Assembly Biosciences stock jumps after Wall Street says Gilead opt-in 'significantly de-risks' genital herpes programs - MSN
Technical Reactions to ASMB Trends in Macro Strategies - Stock Traders Daily
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Yahoo Finance
Why Assembly Biosciences Inc. stock remains a top recommendationVolume Spike Alerts & Outstanding Growth Stocks - bollywoodhelpline.com
Assembly Biosciences price target raised to $40 from $29 at Mizuho - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6%What's Next? - MarketBeat
GILD Exercises Option to License Assembly Bio's Herpes Programs - Eastern Progress
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - BioSpace
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Sahm
Assembly Biosciences (NASDAQ:ASMB) Receives Buy Rating from HC Wainwright - Defense World
Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says HC Wainwright - MSN
Gilead exercises option for Assembly Bio’s herpes treatment programs By Investing.com - Investing.com South Africa
HC Wainwright & Co. Reiterates Assembly Biosciences (ASMB) Buy Recommendation - Nasdaq
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Asianet Newsable
Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Assembly Biosciences rises as Gilead opts to license co's HSV therapies - TradingView — Track All Markets
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
ASMB: HC Wainwright & Co. Reiterates Buy Rating with $50 PT | AS - GuruFocus
Gilead exercises license for Assembly Biosciences herpes programs - Seeking Alpha
Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Program - PharmiWeb.com
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal - GuruFocus
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
Gilead exercises option for Assembly Bio's herpes treatment programs - StreetInsider
Assembly Biosciences (ASMB) Price Target Increased by 24.84% to 48.70 - Nasdaq
Financial Analysis: Teva Pharmaceutical Industries (NYSE:TEVA) versus Assembly Biosciences (NASDAQ:ASMB) - Defense World
Can Assembly Biosciences Inc. stock beat analyst upgradesTrade Risk Assessment & Fast Entry Momentum Alerts - Улправда
What risks investors should watch in Assembly Biosciences Inc. stockJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials - MSN
How Assembly Biosciences Inc. stock performs in rising dollar environmentEntry Point & Reliable Price Breakout Alerts - Улправда
How resilient is Assembly Biosciences Inc. stock in market downturnsEarnings Summary Report & Scalable Portfolio Growth Methods - Улправда
Why Assembly Biosciences Inc. stock could see breakout soon2025 Trade Ideas & Risk Managed Trade Strategies - Улправда
Recap Report: How Assembly Biosciences Inc. stock performs in rising dollar environmentQuarterly Trade Report & Community Verified Watchlist Alerts - Улправда
Can Assembly Biosciences Inc. stock resist market sell offsJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - Улправда
Assembly Biosciences Earnings Notes - Trefis
Assembly Biosciences completes key phase 1a study on ABI-6250 - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Assembly Biosciences Completes Key Phase 1a Study on ABI-6250 - TipRanks
(ASMB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JANUS HENDERSON GROUP PLC Expands Stake in Assembly Biosciences Inc - GuruFocus
Assembly Biosciences (ASMB) Receives a Buy from Guggenheim - The Globe and Mail
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data By Investing.com - Investing.com South Africa
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data - Investing.com Nigeria
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):